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deficiency: Structural insights for
inhibition of the alternative pathwayTo the Editor:
We investigated an alternative complement pathway (AP)
deficiency in a patient with absent alternative pathway hemolytic
activity but normal classical pathway hemolytic activity
recovering from invasive meningococcal infection (for patient
and sibling details, see Patient details in this article’s Online
Repository at www.jacionline.org). Serum reconstitution with
proximal AP components suggested a factor D (FD) deficiency
(Fig 1, A). Sanger sequencing of CFD identified a rare
homozygous missense mutation (c.602G>C) in exon 4 in the
patient (II-1) and sibling (II-2), resulting in an arginine to proline
substitution (p. R176P) (see Fig E1, A, and reference E9 in this
article’s Online Repository at www.jacionline.org). This
genotype cosegregated with an alternative pathway hemolytic
activity–null phenotype, as the parents, both heterozygotes, had
normal alternative pathway hemolytic activity (Fig 1, B). In
contrast to previously confirmed FD deficiencies,1-3 all members
of the pedigree had normal levels of circulating FD, as
corroborated by Western blot (see Fig E1, B). Meanwhile,
identical circular dichroism spectra and melting curves of
recombinant wild-type (WT) and R176P FD precluded gross
changes in FD structure or stability, suggesting a functional
deficiency (Fig 1,C, and see Fig E1,C). We assessed the cleavage
of C3b-bound factor B (FB) by recombinant WT and mutant FD
(R176P, R176A, R176Q). WT FD could cleave C3b-bound FB to
produce fragments Bb and Ba. Conversely, R176P FD
demonstrated diminished in vitro catalytic activity at all
concentrations and had negligible activity at physiological
concentration (0.04 mmol/L) (Fig 1, D, and see Fig E1, D).
Reconstitution of FD-depleted serum with R176P FD also
demonstrated impaired AP-mediated hemolysis (see Fig E1, E).
FD’s serine protease activity depends on obligatory binding to
the C3bB complex via 4 exosite loops (residues 132-135,
155-159, 173-176, 203-209). This leads to rearrangement of the
self-inhibitory loop (199-202), allowing realignment of His41
and Asp89 with Ser183 to form the active catalytic triad (see Fig
E2,A andB, in this article’s Online Repository at www.jacionline.
org).4,5 Mutation R176P lies outside the active site, within one of
the FB-binding exosite loops.We used molecular dynamics (MD)
stimulations to study how the R176P mutation affects the FD
protein fold (see Fig E2, C). In mutant FD, we observed a
rearrangement of the exosite loop 155-161within 50 nanoseconds
of simulation (Fig 2, A). This was unexpected because loop
155-161 was not in direct contact with residue 176. Average
structures generated from the final 50 nanoseconds of simulation
Co
ntr
ol 
se
rum
Pa
tie
nt 
se
rum
Pa
tie
nt 
se
rum
 + 
P
Pa
tie
nt 
se
rum
 + 
FB
Pa
tie
nt 
se
rum
 + 
FD
FD
 on
ly
A
I
II
D/d
121%
2.5
D/d
125%
2.3
d/d
0%
2.3
d/d
0%
2.0
P
CFD genotype:
AP50:
Serum FD [mg/L]:
CFD genotype:
AP50:
Serum FD [mg/L]:
1 2B C
Temperature (°C)
WT
R176P
0.0
0.5
1.0
1.5
40 60 80 100
+ - - - + + + + + + + +
- + - - + + + + + + + +
- - 2.5 - 2.5 - 1 - 0.2 - 0.04 -
- - - 2.5 - 2.5 - 1 - 0.2 - 0.04
250 kDa
C3b
FB
Bb
Ba
FD
150 kDa
100 kDa
75 kDa
50 kDa
37 kDa
25 kDa
20 kDa
C3bD
FB
R176P FD [µM]
WT FD [µM]
FIG 1. Assessing the contribution of mutation R176P to AP dysfunction. A, Alternative pathway hemolytic
activity (AP50) assay assessing patient serum supplemented with properdin (P), FB, or FD. B, The immediate
family pedigree of the patient with the CFD genotype, serum AP50, and serum FD concentrations displayed.
D represents the WT allele and d, the mutant allele (c.602G>C). C, Thermal shift assay of WT and R176P FD.
D, Serial dilutions of recombinant WT or R176P FD were incubated with C3b and FB. The SDS-PAGE gel,
stained with AcquaStain, shows the individual proteins and resultant products.
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FIG 2. Defining the effects of the R176P mutation on FD function. A and B, FB-binding exosite loop 155-167
assumes a new conformation in mutant FD simulation. Arrows highlight average Ca position shifts of 2
residues that bind C3bB in the R176P FD simulation. C, Loss of shape complementarity at the FD-C3bB
interface. FD exosite loops from published cocrystal structures (white, Protein Data Bank ID: 2XWB) overlaid
with the simulated loops of WT and mutant FD. D, Distance sampled between the active site Nε2 nitrogen of
His41 and Og of Ser183 during each simulation. The shorter distance is necessary for catalytic activity. E and
F, Surface plasmon resonance binding measurement of enzymatically inactive recombinant FD (R176P/
S183A or WT/S183A) to C3bB complex. G, Steady state kinetics for Z-Lys-SBzl cleavage by WT, R176P,
R176A, and catalytically inactive control S183A FD. RMSD, Root-mean-square deviation.
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key FB-binding residues Asp161 and Arg157 were shifted by
4.3 A and 1.9 A, respectively (Ca average position) (Fig 2, B).
Superimposing these MD average structures onto the crystal
structure of the C3bB-D complex revealed that Asp161 and
Arg157 assumed a conformation that no longer supported binding
due to loss of shape and charge complementarity to the FB surface
(Fig 2, C). The other 3 exosite loops retained their
binding-competent conformations. After assuming the new
conformation, exosite loop 155-161 demonstrated higher
conformational mobility (root mean square fluctuation) relative
to WT (Fig E2, D and E). In contrast, the mobility of loops
containing catalytic residues His41 and Asp89 decreased in the
mutants. Using the distance between His41 and Ser183 during
MD simulations as a proxy for the active site conformation, we
observed that WT could sample the short distance necessary for
a catalytically active conformation (Fig 2, D). Conversely, in
both mutant simulations, the distance remained larger, consistent
with His41 pointing away from the active site. Therefore, inaddition to disruption of key FB-binding residues, mutations
R176P and R176A appear to stabilize the self-inhibited
conformation of free FD.
To assess the binding of FD to C3bB, we used surface plasmon
resonance. Coinjection of catalytically inactive FD (WT/S183A)
with FB demonstrated a dose-dependent increase in binding to
C3b and complex formation (Fig 2, E). In contrast, R176P/S183A
FD lacked any detectable binding (Fig 2, F). Consistent with the
stochastic transitions of free WT FD to the active conformation
observed in the MD simulation, FD has a low level of esterolytic
activity toward a small synthetic substrate, Z-Lys-SBzl (Fig 2,D).
Surprisingly, R176P FD demonstrated a loss of esterolytic
activity similar to the active site mutant, S183A (see Fig 2, G).
Deficiency of properdin, the most common AP deficiency, can
result from absent (type I), low (type II), or normal
but nonfunctioning (type III) protein levels (for reference,
see reference E10 in this article’s Online Repository
at www.jacionline.org). Meanwhile, previously confirmed
deficiencies of activating complement serine proteases have all
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unique deficiency: R176P FD is fully expressed and stable, but
enzymatically inert, constituting a functional or type III
deficiency. Recent preclinical evidence6 that FD-deficient mice
are susceptible to diabetes prompted metabolic assessment in
the FD-deficient patients. No abnormality was detected (for
details, see Functional FD deficiency does not result in impaired
oral glucose tolerance section, Fig E3, and Table E1 in this
article’s Online Repository at www.jacionline.org).
Overactivation of AP is implicated in numerous inflammatory
disorders, including age-relatedmacular degeneration. Therefore,
blockade of the AP by targeting the rate-limiting enzyme, FD, is
an attractive approach to controlling disease progression. An
anti-FD Fab fragment targeting the 2 distal exosite loops has
shown some benefit in phase II clinical trials for treatment of dry
age-related macular degeneration.7 In vitro studies indicate that it
inhibits binding to the C3bB complex but increases esterolytic
activity toward small-molecule substrates.8 This may result in
unwanted clinical effects due to nonspecific activity or limit its
efficacy in vivo. In the case of R176P FD, both FB-binding and
esterolytic activity are abrogated through exosite hindrance and
stabilization of the self-inhibited state. Loop 173-176 is thus a
promising target for allosteric inhibitors of FD that stabilize the
inhibitory loop in addition to binding-blockade. A structure-
based design approach to targeting FD has recently succeeded
in identifying candidate FD inhibitors where high-throughput
screens had failed,9 highlighting the benefits of integrating
structural information into candidate drug screens. Comprehen-
sive definition of the structural and molecular determinants of
in vivo FD activity is critical for this. This study of the R176P
mutation demonstrates how in-depth mechanistic analysis of
rare complement deficiencies can deliver such insight validated
clinically by in vivo human evidence of AP blockade.
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